Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 8, 2014, Pages 1413-1419

  Izumi, Kouji ^a   Lin, Wen Jye ^b   Miyamoto, Hiroshi ^c   Huang, Chiung Kuei ^d   Maolake, Aerken ^a   Kitagawa, Yasuhide ^a   Kadono, Yoshifumi ^a   Konaka, Hiroyuki ^a   Mizokami, Atsushi ^a   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

Castration resistant prostate cancer; Gleason score; Prostate cancer; Prostate specific antigen; TNM classification

Indexed keywords

ANTIANDROGEN; BIOLOGICAL MARKER; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; ETHINYLESTRADIOL; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER SPECIFIC SURVIVAL; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; RISK; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84904331571     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1681-8     Document Type: Article

References (19)

1. Andriole GL, Crawford ED, Grubb RL III et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319
2. Cooperberg MR, Hinotsu S, Namiki M et al (2009) Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 27:4306-4313
3. D'Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974 (Pubitemid 28445094)
4. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-781
5. Hinotsu S, Akaza H, Usami M et al (2007) Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol 37:775-781 (Pubitemid 350120301)
6. Izumi K, Kadono Y, Shima T et al (2010) Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients. Anticancer Res 30:5201-5205
7. Jang JY, Kim YS (2012) Is prostate biopsy essential to diagnose prostate cancer in the older patient with extremely high prostate-specific antigen? Korean J Urol 53:82-86
8. Kitagawa Y, Hinotsu S, Shigehara K et al (2013) Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation. Int J Urol 20:708-714
9. Kojima S, Suzuki H, Akakura K et al (2004) Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 171:679-683 (Pubitemid 38090455)
10. Matsumoto K, Tanaka N, Hayakawa N et al (2013) Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in cas-tration- resistant prostate cancer patients: report of 102 cases and review of literature. Med Oncol 30:717
11. Naito S, Kuroiwa K, Kinukawa N et al (2008) Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer. J Urol 180:904-909 discussion 909-10
12. Narimoto K, Mizokami A, Izumi K et al (2010) Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen. Int J Urol 17:337-345
13. Partin AW, Mangold LA, Lamm DM et al (2001) Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58:843-848 (Pubitemid 34017254)
14. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520 (Pubitemid 39315318)
15. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882 (Pubitemid 38807610)
16. Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328
17. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-30
18. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512 (Pubitemid 39315317)
19. Ueno S, Mizokami A, Fukagai T et al (2013) Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study. Anticancer Res 33:3837-3844